Overview

Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease

Status:
Withdrawn
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study in patients with stage 4 and 5 chronic kidney disease is to determine whether rosiglitazone can reduce inflammatory markers and to investigate its effect on intima media thickness, calcification and pulse wave velocity.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Leiden University Medical Center
Treatments:
Anti-Inflammatory Agents
Rosiglitazone